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The HIV epidemic is a major threat to health in the developing and western worlds. A
modality that targets and kills HIV-1-infected cells could have a major impact on the treatment
of acute exposure and the elimination of persistent reservoirs of infected cells. The aim of this
proof-of-principle study was to demonstrate the efficacy of a therapeutic strategy of targeting
and eliminating HIV-1-infected cells with radiolabeled antibodies specific to viral proteins in
vitro and in vivo.
Methods and Findings
Antibodies to HIV-1 envelope glycoproteins gp120 and gp41 labeled with radioisotopes
bismuth 213 (
213Bi) and rhenium 188 (
188Re) selectively killed chronically HIV-1-infected human
T cells and acutely HIV-1-infected human peripheral blood mononuclear cells (hPBMCs) in vitro.
Treatment of severe combined immunodeficiency (SCID) mice harboring HIV-1-infected
hPBMCs in their spleens with a
213Bi- or
188Re-labeled monoclonal antibody (mAb) to gp41
resulted in a 57% injected dose per gram uptake of radiolabeled mAb in the infected spleens
and in a greater than 99% elimination of HIV-1-infected cells in a dose-dependent manner. The
number of HIV-1-infected thymocytes decreased 2.5-fold in the human thymic implant grafts of
SCID mice treated with the
188Re-labeled antibody to gp41 compared with those treated with
the
188Re-control mAb. The treatment did not cause acute hematologic toxicity in the treated
mice.
Conclusions
The current study demonstrates the effectiveness of HIV-targeted radioimmunotherapy and
may provide a novel treatment option in combination with highly active antiretroviral therapy
for the eradication of HIV.
The Editors’ Summary of this article follows the references.
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The HIV epidemic is a major threat to health in the
developing and western worlds. Highly active antiretroviral
therapy (HAART), a combination of drugs that inhibits
enzymes essential for HIV-1 replication, can reduce the
viremia and the onset of opportunistic infections in most
patients and prolong survival [1]. However, HAART regimens
are complicated and have signiﬁcant toxicity [2–5]. Repli-
cation-competent virus that persists in infected cells emerges
rapidly after the cessation of HAART [6–9]. The inability to
eliminate HIV-1-infected cells also limits the time frame in
which HAART initiated after exposure to HIV-1 can prevent
infection [7]. Unless HAART is initiated within days of
exposure, HIV infection of a nominal number of cells may be
sufﬁcient to develop sustained infection despite subsequent
long-term HAART [10,11]. Once the clinical role of reservoir
reduction is clariﬁed, and under circumstances in which
expected beneﬁt outweighs safety considerations, a modality
that targets and kills HIV-1-infected cells may become
important for the treatment of acute exposure and elimi-
nation of persistent reservoirs of infected cells. To speciﬁcally
kill HIV-1-infected cells, several approaches have been tried
[12], including toxin-coupled antibodies that are directed at
HIV-1-encoded envelope proteins and can eliminate infected
cells [13,14], but none of these strategies has yet been shown
to be effective in humans.
Radioimmunotherapy (RIT) takes advantage of the specif-
icity of the antigen–antibody interaction to deliver lethal
doses of radiation to target cells using radiolabeled anti-
bodies [15]. Currently RIT is successfully used to treat of
certain cancers. We demonstrated the usefulness of RIT for
infectious diseases by treating murine cryptococcosis with a
monoclonal antibody (mAb) to the Cryptococcus neoformans
capsular glucuronoxylomannan labeled with bismuth 213
(
213Bi) or rhenium 188 (
188Re) [16], and extended the
applicability of RIT to treatment of a bacterial infection
[17]. We also recently suggested that RIT may be effective
against chronically infected cells, including those with viral
infections [18]. In contrast to RIT for fungal and bacterial
diseases in which the target is the microbe, RIT for viral
diseases targets the infected cells and consequently provides a
general strategy for eliminating reservoirs of infected cells
capable of producing infectious viruses. This approach could
be particularly useful for treatment of drug-resistant HIV
strains, which present an ever-increasing problem [19]. In the
current proof-of-principle study, we examined the effective-
ness of targeting and eliminating HIV-1-infected cells with
radiolabeled antibodies to viral proteins.
Methods
Antibodies
Goat polyclonal antibodies against gp120 (IgG) used in
preliminary in vitro experiments was purchased from Biode-
sign International (Saco, Maine, United States). Murine 18B7
mAb (IgG1) to C. neoformans [20] was used as an irrelevant
control. Human mAb to gp41, 246-D (cluster I), was produced
as described [21]. Human mAb 1418 (IgG1) to parvovirus B19
[22] was used as an irrelevant control for mAb 246-D, and
human mAb 447 (IgG3) to the V3 loop of HIV-1 gp120 [23]
was used as a positive control in the FACS studies. Antibodies
were puriﬁed by protein A or G chromatography prior to
labeling.
Radioisotopes and Radiolabeling of the Antibodies
Antibodies were labeled with alpha-emitter
213Bi (half-life
45.6 min) obtained from
225Ac generator as described in [24]
or with beta-emitter
188Re (half-life 16.9 h) as described in
[16].
In Vitro Killing of ACH-2 Cells and Human PBMCs with
Radiolabeled mAbs
The ACH-2 cell line is a latent T cell clone infected with
HIV-IIIB that produces steady low levels of viruses that is
markedly increased by stimulation with phorbol myristate; it
was obtained through the National Institutes of Health (NIH)
AIDS Research and Reference Reagent Program (Division of
AIDS, National Institute of Allergy and Infectious Diseases,
NIH: ACH-2, #349, from Dr. Thomas Folks). At 48 h after
stimulation with phorbol myristate, ACH-2 cells cultured in
triplicate wells were treated with 0–50 lCi (0–1.85 MBq) of
188Re-labeled anti-gp120 or the irrelevant control mAb 18B7;
or 0–20 lCi (0–0.74 MBq) of
213Bi-labeled anti-gp120 or mAb
18B7 or with matching amounts (2.5–12.5 lg) of ‘‘cold’’
(unlabeled) anti-gp120 mAb. Approximately 2 3 10
5 cells
were used for each condition. The cells were incubated with
radiolabeled or cold mAbs at 37 8C for 3 h, transferred into
fresh cell culture medium, and then incubated in 5% CO2 at
37 8C for 72 h. The number of viable cells was then assessed by
Trypan blue dye exclusion assay.
The effect of radiolabeled HIV-1 glycoprotein-binding
mAbs on HIV-1-infected cells was studied in vitro using
human peripheral blood mononuclear cells (hPBMCs) ob-
tained from New York Blood Center (New York, New York,
United States). hPBMCs were stimulated with phytohemag-
glutinin (PHA) and interleukin-2 for 48 h and then infected
with HIV-1 strain JR-CSF (NIH AIDS Research and Reference
Reagent Program, National Institute of Allergy and Infectious
Diseases, NIH: HIV-1JR-CSF, #394, from Dr. Irvin S. Y. Chen).
Although the number of ACH-2 cells infected with HIV-1 was
almost 100%, only a fraction (;10%–30%) of the hPBMCs
were infected with HIV-1 as determined by limiting dilution
coculture technique [25]. Subsequently in the text we refer to
the cells exposed to HIV-1 as ‘‘infected’’ cells and those that
were not exposed to the virus as ‘‘noninfected’’ cells. At 48 h
after infection, infected cells cultured in triplicate wells were
treated with
213Bi-labeled mAb 246-D, or
213Bi-labeled
irrelevant control mAb 1418, or matching amounts of cold
246-D, as above. To verify that 246-D did not bind to the
surface of noninfected hPBMCs, noninfected cells were
subjected to treatment with
213Bi-246-D or
188Re-246-D.
The number of viable cells was then assessed by Trypan blue
dye exclusion assay.
Flow Cytometric Analysis of mAbs Binding to Virus-
Infected Cells
Binding studies of human mAbs to the surface of hPBMCs
infected with HIV-1JR-CSF were performed as described
previously [26]. Brieﬂy, PHA-stimulated hPBMCs were in-
fected with 1 ml of stock HIV-1JR-CSF virus and cultured for 13
d in medium supplemented with human recombinant
interleukin-2 (20 U/ml; Boehringer Mannheim Biochemicals,
Indianapolis, Indiana, United States). The cells in duplicate
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mAb Targeting of Virally Infected Cellswells were incubated with each human mAb at 10 lg/ml for 1
h on ice, washed and reincubated with phycoerythrin-labeled
goat F(ab9)2 anti-human IgG(c) (Caltag Laboratories, Burlin-
game, California, United States). Using a FACScan ﬂow
cytometer (Becton Dickinson, Palo Alto, California, United
States), live lymphocytes were selected for analysis by gating
with forward and 908 scatter. The negative control consisted
of cells from infected cultures stained with the conjugated
anti-IgG in the absence of a human mAb.
Treatment of HIV-1 Infection in Intrasplenically Infected
SCID Mice with Radiolabeled mAbs
The procedures used in animal studies described below
were reviewed and approved by the Albert Einstein College of
Medicine Animal Institute Committee. These experiments
utilized a mouse model; ﬁrst, PHA-activated hPBMCs were
infected with HIV-1JR-CSF as described above, then 48 h later
these infected hPBMCs were injected intrasplenically (25 3
10
6 cells per mouse) into SCID mice. Mice were treated
intraperitoneally 1 h later with one of the following: 20 lgo f
cold 246-D (n¼4); 100 lCi (3.7 MBq) (20 lg) of
213Bi-1418 (n¼
5) or 80 lCi (2.96 MBq) (20 lg) of
188Re-1418 (n¼3) as isotype-
matching controls; or 80 lCi (2.96 MBq) (20 lg) of
188Re-246-
D( n¼4) or 100 lCi (3.7 MBq) (20 lg) of
213Bi-246-D (n¼5). In
one experiment mice were given 80 lCi (2.96 MBq) (20 lg) of
188Re-246-D intraperitoneally (IP) 1 h prior to infection with
infected hPBMCs (n ¼ 4). In dose-response experiments mice
were injected IP with
188Re-246-D (20 lg) with activity of 40
lCi (1.48 MBq) (n¼4), with 160 lCi (5.92 MBq) (n¼4), with 20
lg of cold 246-D (n ¼ 4), or with no treatment (n ¼ 4). Mice
were sacriﬁced and spleens were harvested and processed 72
h postinjection. The number of HIV-1-infected cells present
in the spleen was measured using limiting dilution quantita-
tive coculture as described [25]. This technique measures the
number of cells capable of producing infectious HIV-1.
Cells isolated from each spleen were diluted 5-fold (in the
range 1 3 10
6 to 3.2 3 10
2 cells) and cultured in duplicate at
37 8C in 24-well culture plates with PHA-activated hPBMCs (1
3 10
6 cells) in 2.0 ml of RPMI 1640 medium containing fetal
calf serum (10% vol/vol) and interleukin-2 (32 U/ml). The
HIV-1 p24 antigen content of the supernatant was measured
1 wk later, using the HIV-1 p24 core proﬁle ELISA (DuPont-
NEN, Boston, Massachusetts, United States). The lowest
number of added cells that infected at least half the duplicate
cultures with HIV-1 was determined; this number repre-
sented the frequency of cells productively infected with HIV-
1 in each spleen, reported as the tissue culture-infecting dose
causing 50% infection (TCID50)/10
6 splenocytes. For example,
if coculture of 10
6 cells was positive and coculture of 2 3 10
5
cells was negative, we assigned this a value of 1 TCID50/10
6
cells because 10
6 cells was the lowest number of cells that
generated productive infection.
Determination of Splenic Uptake of Radiolabeled mAbs
Two groups of SCID mice (four mice per group) were used
in this experiment. One group was injected intrasplenically
with HIV-1-infected hPBMCs (25 3 10
6 cells/ mouse) and
another with noninfected hPBMCs (20 3 10
6 cells/ mouse) as
described above. After 1 h, 20 lCi (0.74 MBq) (20 lg) of
188Re-
246-D was given IP to each mouse, and at 3 h postinjection
the animals were sacriﬁced, their spleens removed and
weighed, radioactivity counted in a gamma counter, and the
percentage of injected dose per gram (ID/g) calculated.
Determination of Platelet Counts in Mice Treated with
Radiolabeled mAbs
Platelet counts were used as a marker of RIT toxicity in
treated animals. For measurement of platelet counts, the
blood of SCID mice (ﬁve mice per group) injected intra-
splenically with HIV-1-infected hPBMCs and either treated
with 100 lCi (3.7 MBq) (20 lg) of
213Bi-246-D or with 160 lCi
(5.92 MBq) (20 lg) of
188Re-246-D IP 1 h after treatment with
infected hPBMCs or untreated was collected from the tail
vein into 200 ll of 1% ammonium oxalate on days 0, 3, 8, and
15 days post-therapy. Platelets were counted in a hemocy-
tometer, using phase contrast, at 4003 magniﬁcation, as
described in [27].
Construction of thy/liv-SCID-hu Mice and Titration of HIV-
1-Infected Mononuclear Cells in the hu-thy/liv Implant by
Limiting Dilution Coculture
The thy/liv-SCID-hu mice. were constructed by implanting
SCID mice (6–8 wk old) with human fetal thymic and liver
tissue under the kidney capsules of SCID mice as described
[28]. Brieﬂy, after SCID mice were anesthetized with
pentobarbital (40–80 mg/kg), approximately ten pieces of
syngeneic human fetal thymic and liver tissue were implanted
under the kidney capsules, and 3 mo later the size of
implanted tissue had increased by more than 20-fold.




(A) ACH-2 cells treated with anti-gp120 labeled with
188Re. The mAb
18B7 radiolabeled with
188Re was used as a irrelevant control.
(B) ACH-2 cells treated with anti-gp120 labeled with
213Bi. The mAb 18B7
radiolabeled with
213Bi was used as an irrelevant control.
In both experiments the number of surviving cells was determined by
Trypan blue dye exclusion. Samples were done in triplicate. Every data
point represents the mean of three replicates and error bars show
standard error of the mean.
doi:10.1371/journal.pmed.0030427.g001
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mAb Targeting of Virally Infected CellsBiodistribution of mAb
188Re-246-D in thy/liv-SCID-hu
Mice
Three thy/liv-SCID-hu mice were infected with HIV-1JR-CSF
via its thymic implant, as described above. Only one implant
in each mouse (each mouse had two implants) was infected.
Three thy/liv-SCID-hu mice with noninfected implants were
used as controls. At 8 d postinfection mice were injected IP
with
188Re-246-D (60 lCi (2.22 MBq), 20 lg of mAb) and
sacriﬁced to assay for biodistribution 18 h later. Only the
infected implant was taken out to check biodistribution. The
blood and major organs were removed, weighed, and counted
in a gamma counter, and the percentage of ID/g was
calculated.
Treatment of HIV-1 Infection in Infected thy/liv-SCID-hu
Mice with Radiolabeled mAbs
Thy/liv-SCID-hu mice were infected by direct injection of
HIV-1JR-CSF (800 TCID50) into the human thymic implant.
Selected implants were biopsied 1 wk later, and the number
of HIV-1-infected thymocytes was quantiﬁed by limiting
dilution coculture. One group of mice (four mice) was treated
with
188Re-246-D (160 lCi (5.92 MBq), 20 lg mAb) and
another group (four mice) with the same activity of
188Re-
1418. After 72 h, the mice were sacriﬁced and the number of
HIV-1-infected thymocytes was determined by quantitative
coculture.
Statistical Analysis
The statistical aspects of data analysis were discussed with
Dr. Y. Lo, a statistician at the Einstein/Monteﬁore Medical
Center, Center for AIDS Research. The sample sizes in animal
experiments were preplanned taking into consideration
availability of animals. The observers were fully blinded to
the active or control nature of the experimental arm being
assayed. The differences between the numbers of TCID50/10
6
splenocytes for differently treated groups during in vivo
therapy studies were analyzed by nonparametric Mann-
Whitney test using Prism software (GraphPad, San Diego,
California, United States). Differences were considered
statistically signiﬁcant when p-values were below 0.05.
Results
To determine the ability of RIT to kill HIV-1-infected cells,
goat polyclonal antibodies to gp120 were labeled with
radioisotopes with distinctly different emission character-
istics—
213Bi (a radioisotope that emits alpha particles, which
are He atoms with a charge ofþ2 and mass of 4) and
188Re (a
radioisotope that emits high-energy beta particles [elec-
trons]).
213Bi and
188Re have different emission ranges in
tissue: 50–80 lm for
213Bi versus 10 mm (on average) for
188Re. Both radioisotopes have been used in preclinical and
clinical settings [29–31]; we used both to investigate if HIV-1-








mAb), or cold anti-gp120. Substantial killing of ACH-2 cells
with
188Re-anti-gp120 polyclonal antibody was observed
compared to the minimal effect of the control Ab linked to
188Re with the same speciﬁc radioactivity or with cold anti-
gp120 Ab (Figure 1A). Elimination of the ACH-2 cells was not
complete. By virtue of their mass, charge, and energy the
relative biological effectiveness of alpha particles is signiﬁ-
cantly higher than that of beta particles emitted by
188Re
[32,33]. Therefore, we examined the effectiveness of the anti-
gp120 linked to the alpha particle emitter
213Bi for killing
HIV-1-infected cells. Almost all of the ACH-2 cells were killed
by 5 lCi (0.185 MBq) of
213Bi-anti-gp120 compared to the
minimal cytocidal activity of an irrelevant mAb linked to
213Bi or cold anti-gp120 Ab (Figure 1B).
Because the HIV envelope protein gp120 is expressed
extracellularly, it was the initial target for antibody-directed
killing of HIV-infected cells. However, toxins coupled to
gp41-speciﬁc antibodies were reported to be more effective
for in vivo elimination of HIV-1-infected cells than were
toxins linked to anti-gp120 [14,26,34]. An advantage of
targeting gp41 over gp120 with antibodies is that gp41 is a
transmembrane protein that is reliably expressed on the
surface of infected cells, is not readily shed, and has a highly
conserved sequence [35]. Therefore, we examined the ability
of radioisotopes coupled to a human mAb speciﬁc for gp41 to
target and kill HIV-1-infected hPBMCs in vitro and in vivo.
For these studies, we used the human anti-gp41 mAb 246-D,
Figure 2. In Vitro Binding and Killing of HIV-Infected Human PBMCs with
Human Monoclonal Antibodies
(A) Binding of 246-D human mAbs to HIV gp41 was determined by flow
cytometry of hPBMCs infected with the JR-CSF strain of HIV-1. Human
mAb 1418 (IgG1) to parvovirus B19 was used as an irrelevant control, and
human mAb 447 (IgG3) to the V3 loop of HIV-1 gp120 (26) was used as a
positive control for the FACS studies. No significant staining was
detected after incubation of HIV-infected cells with the conjugated anti-
human IgG in the absence of a primary human mAb. Samples were
analyzed in duplicate.
(B) HIV-infected hPBMCs were treated with
213Bi-246-D, cold 246-D, and
213Bi-1418 (irrelevant control), and noninfected hPBMCs were treated
with
213Bi-246-D. The number of surviving cells was determined by
Trypan blue dye exclusion assay. Samples were analyzed in triplicate.
Every data point represents the mean of two (A) or three (B) replicates;
error bars in (B) show standard error of the mean.
doi:10.1371/journal.pmed.0030427.g002
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mAb Targeting of Virally Infected Cellswhich binds speciﬁcally to HIV-1-infected cells as demon-
strated by ﬂow cytometry of hPBMCs infected with HIV-1JR-
CSF (Figure 2A). 246-D does not bind to the six-helix bundle
that forms after gp120 CD4 intervention, but rather to an
epitope, near the disulﬁde loop of gp41, that is an
immunodominant epitope [36] and is broadly cross-reactive
with genetically diverse HIV-1 strains [37,38]. When 246-D
was linked with
213Bi, it was very effective in eliminating HIV-
1-infected hPBMCs when compared to cold 246-D and the
irrelevant mAb 1418 labeled with
213Bi (Figure 2B). We
observed that more hPBMCs were killed by
213Bi-246-D than
overall percentage of infected cells in the sample. This most
likely reﬂects a ‘‘cross-ﬁre’’ effect from alpha particles
emanating from adjacent HIV-1-infected cells that contained
bound
213Bi-mAb in the setting of cell crowding at the
bottom of tissue culture wells. Importantly, in the absence of
HIV-1 antigens, incubation of noninfected hPBMCs with
213Bi-246-D produced no signiﬁcant killing of the cultured
cells (Figure 2B), and no killing of noninfected hPBMCs was
observed post-treatment with
188Re-246-D as well (unpub-
lished data).
We next examined the in vivo ability of RIT with radio-
labeled 246-D to eliminate HIV-1-infected cells. For these
studies, hPBMCs infected with HIV-1JR-CSF were injected into
the spleens of SCID mice and the mice were treated as
indicated. We used a 80 lCi (2.96 MBq) dose for
188Re-246-D
Figure 3. RIT of SCID Mice Injected Intrasplenically with HIV-1JR-CSF-Infected Human PBMCs with
188Re- and
213Bi-Labeled Human Anti-gp41 mAb 246-D
(A) Mice were treated IP 1 h after infection with infected hPBMCs with either 20 lg of cold 246-D (n¼4); 100 lCi (3.7 MBq) (20 lg) of
213Bi-1418 (n¼5)
or 80 lCi (2.96 MBq) (20 lg) of
188Re-1418 (n¼3) as isotype-matching controls; 80 lCi (2.96 MBq) (20 lg) of
188Re-246-D (n¼4); or 100 lCi (3.7 MBq) (20
lg) of
213Bi-246-D (n¼5). One group was left untreated (n¼4). Another group of mice were given 80 lCi (2.96 MBq) (20 lg) of
188Re-246-D IP 1 h before
infection with infected hPBMCs (n ¼ 4).
(B) Mice were injected IP with
188Re-246-D (20 lg) with activity of 40 lCi (1.48 MBq) (n¼4), with 160 lCi (5.92 MBq) (n¼4), or with 20 lg of cold 246-D
(n¼4). A fourth group was untreated (n¼4). The number of HIV-1-infected hPBMCs in the spleens were then determined by limiting dilution coculture
and presented as TCID50/10
6 splenocytes. Each bar represents the mean of TCID50/10
6 splenocytes in a given group of mice, and error bars show
standard error of the mean.
doi:10.1371/journal.pmed.0030427.g003
PLoS Medicine | www.plosmedicine.org November 2006 | Volume 3 | Issue 11 | e427 2098
mAb Targeting of Virally Infected Cellsand 100 lCi (3.7 MBq) for
213Bi-246-D, because these doses
were therapeutic and safe in experimental RIT of fungal and
bacterial infections [17,39]. The mice were evaluated 72 h
later for the presence of residual HIV-1-infected cells by
quantitative coculture [25]. The 72 h time period was chosen
to give the sufﬁcient time for the
188Re-labeled mAb to
deliver a lethal dose of radioactivity to the cells, as
188Re half-
life is 16.9 h and several half-lives are required for a given
radionuclide to deliver the dose to the target. Treatment of
mice with
188Re-labeled mAb 246-D administered either
before or after intrasplenic injection with HIV-1JR-CSF-
infected hPBMCs dramatically reduced the subsequent
number of HIV-1-infected cells (p ¼ 0.016 and p ¼ 0.008,
respectively). Infected cells were also killed after treatment of
mice with
213Bi-246-D (Figure 3A) (p¼0.008). In contrast, the
administration of the matching amounts of cold 246-D (p ¼
1.0) or of a radioisotope-coupled irrelevant control mAb did
not reduce the average number of infected cells in the SCID
mouse spleens (p ¼ 1.0 and p ¼ 0.06 for
188Re- and
213Bi-
labeled control mAb, respectively). It is likely that
188Re-246-
D was more effective in vivo than
213Bi-246-D due to the
longer physical half-life of
188Re (16.9 h versus 46 min), which
allowed the labeled mAbs to reach infected cells while still
carrying a high-activity ‘‘payload.’’
To investigate the dose-response effect, the mice were
treated with 40 and 160 lCi of
188Re-246-D, corresponding to
50% and 200% of the therapeutic dose, respectively. While 40
lCi (1.48 MBq)
188Re-246-D was not effective in killing HIV-
infected hPBMCs in vivo (p ¼ 1.0), 160 lCi (5.92 MBq) dose
almost completely eliminated the HIV-infected cells (p¼0.03)
(Figure 3B).
To further investigate the speciﬁcity of radiolabeled mAb
binding to gp41 on HIV-infected hPBMCs we compared the
splenic uptake of
188Re-246-D in mice injected intraspleni-
cally with noninfected hPBMCs and HIV-1-infected hPBMCs.
The uptake expressed as percentage of ID/g of spleen (with
standard deviation) was 8% 6 4% and 57% 6 10% ID/g for
noninfected and infected hPBMCs, respectively. This result
indicates that the
188Re-246-D was targeted in vivo to HIV-1-
infected cells.
We evaluated the hematological toxicity of radiolabeled
246-D during HIV-1 infection in the SCID mice by platelet
counts. The platelet count nadir usually occurs 1 wk after
radiolabeled antibody administration to tumor-bearing ani-
mals [40,41]. We did not observe any changes in platelet
counts in mice treated with 100 lCi (3.7 MBq) of
213Bi-246-D
on days 4, 8, and 15 post-treatment compared to nontreated
infected controls; platelet counts were stable at 1.5 3 10
9 (6
0.2 3 10
9) platelets/ml of blood (unpublished data). For mice
given 160 lCi of
188Re-246-D—the highest dose used in this
study—a slight nonsigniﬁcant drop in platelet count was
noted on day 7 post-treatment, but counts returned to
normal by day 15 (Figure 4). This lack of hematologic toxicity
likely reﬂects the very speciﬁc targeting of HIV-1-infected
hPBMCs by radiolabeled mAb, since gp41 antigen is ex-
pressed only on infected cells in the mouse. In fact, one of the
advantages of using RIT to treat infections as opposed to
cancer is that, in contrast to tumor cells, cells expressing
microbial antigens are antigenically very different from host
tissues and thus provide the potential for exquisite speciﬁcity
and low cross-reactivity. This safety proﬁle is compatible with
our previous data showing that RIT was also relatively
nontoxic in mouse models of experimental fungal and
bacterial infection [17,39]. A large therapeutic window is
available because the therapeutic effect was achieved with
activities signiﬁcantly lower than reported maximum toler-
ated activity for
188Re-labeled (800 lCi (29.6 MBq) for
intravenous injection [42]) and
213Bi-labeled IgGs (in excess
of 1,000 lCi (37 MBq) when given IP [42]). In this regard, IP
administration of the radiolabeled mAbs utilized in our study
has proved to be better tolerated than the intravenous route
[42], and it helps to circumvent the problem of often
relatively low speciﬁc activity of radiolabeled mAbs (in mCi/
ml) by allowing the administration of higher volumes than
during intravenous administration.
To further examine the in vivo capacity of RIT to target
and eliminate HIV-1-infected lymphocytes, we utilized our
well-characterized thy/liv-SCID-hu mouse model [43–45]. This
system uses SCID mice implanted under their kidney capsules
with fetal human thymic and liver tissue that develops into a
structure closely resembling a human thymus; this thymic
implant is readily infectible with clinical isolates of HIV-1.
This mouse model can be used to evaluate the in vivo capacity
of candidate anti-HIV agents to inhibit HIV-1 infection
[43,45,46]. Initially we measured the biodistribution of IP-
injected
188Re-246-D in thy/liv-SCID-hu mice with HIV-
infected and noninfected thymic implants (Table 1). The
uptake of 246-D in infected implants was higher than in
noninfected implants; however, the overall uptake in the
infected implants 18 h postinjection was modest, most likely
due to the relatively poor vascularization of the implants. We
have previously demonstrated that HIV-1-infected thy/liv-
SCID-hu mice develop HIV plasma viremia, which may
correlate with the higher uptake of 246-D in the blood as
well as spleen, liver, and kidneys of the HIV-infected mice.
Because uptake of the radiolabeled anti-gp41 mAb in
infected implants of thy/liv-SCID-hu was modest after IP
injection, the therapy experiments were performed using
intraimplant injections of radiolabeled mAbs to accommo-
date the predominantly murine vasculature of the implant,
Figure 4. Effect of RIT on Platelet Counts in the Peripheral Blood
Platelet counts in the blood of SCID mice injected intrasplenically with
HIV-1-infected hPBMCs and either treated with 160 lCi (5.92 MBq) (20
lg)
188Re-246-D IP 1 h after infection with hPBMCs (n ¼ 5) or no
treatment (n¼5). The blood was collected from the tail vein on days 0, 4,
8, and 15 post-therapy. Each data point represents the mean of platelet
counts in a given group of mice, and error bars show standard error of
the mean.
doi:10.1371/journal.pmed.0030427.g004
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labeled antibody. Sufﬁcient blood supply to the tissue treated
with RIT is crucial for successful treatment, as it has been
established that early in RIT development antibodies mostly
localize along the blood vessels [47]. As shown in Figure 5A,
there was a 2.5-fold reduction in the number of HIV-1-
infected thymocytes in the human thymic implant grafts of
mice treated with
188Re-246-D compared to those treated
with the
188Re-control mAb. To directly conﬁrm the anti-HIV
effect of the
188Re-anti-gp41 treatment, we compared the
level of infection in the human thymic implants of a biopsy
taken before treatment with the degree of infection after
treatment. The mean number of HIV-infected thymocytes
was reduced more than 95% by
188Re-anti-gp41 in three of
the four treated mice (Figure 5B). Taken together, these
results demonstrate that RIT using
188Re-anti-gp41 mAb
potently and selectively eliminates HIV-1-infected cells.
Discussion
We have demonstrated that the antibodies to HIV-1
envelope glycoproteins gp120 and gp41 labeled with radio-
isotopes
213Bi and
188Re selectively killed chronically HIV-1-
infected human T cells and acutely HIV-1-infected human
peripheral blood mononuclear cells (hPBMCs) in vitro.
Treatment of SCID mice harboring HIV-1-infected hPBMCs
in their spleens with a
213Bi- or
188Re-labeled monoclonal
antibody to gp41 viral protein resulted in a greater than 99%
elimination of HIV-1-infected cells in a dose-dependent
manner. The number of HIV-1-infected thymocytes de-
creased 2.5-fold in the human thymic implant grafts of SCID
mice treated with the
188Re-labeled antibody to gp41
compared with those treated with the
188Re-control mAb.
The treatment did not cause acute hematologic toxicity in the
treated mice.
In cancer treatment, the success of FDA-approved drugs
such as Zevalin and Bexxar (anti-CD20 mAbs labeled with
yttrium 90 [
90Y] and iodine 131 [
131I], respectively) in the
treatment of relapsed or refractory B cell non-Hodgkin
lymphoma is proof of the enormous potential of RIT for
targeted elimination of malignant cells and for treatment of
patients who have failed all standard therapeutic regimens.
Recent encouraging reports on the use of RIT as an initial
treatment for follicular lymphoma [48] are making RIT a
ﬁrst-line anticancer therapy. This clinical experience using
RIT creates a favorable environment for the introduction and
use of RIT for treating HIV-1-infected patients. The
effectiveness of RIT for HIV-1 infection is enhanced because
the majority of long-lived infected cellular targets are
lymphocytes, which are among the most radiosensitive cells
in the body.
RIT of HIV-1 has ﬁve marked advantages over the
immunotoxin approach. (1) The antibody used for radiation
delivery does not need to be internalized to kill the cell. (2)
Not every infected cell in the body needs to be targeted by the
antibody because of the ‘‘cross-ﬁre’’ effect. Consistent with
this mechanism,
188Re-labeled mAbs may be more effective in
vivo than in vitro (Figures 1A and 3A). In vitro, the ‘‘cross-
ﬁre’’ radiation is largely deposited on the two-dimensional
surface represented by the cell layer at the bottom of a tissue
culture well, whereas in vivo there are many infected cells in
the nearby three-dimensional space such that ‘‘cross-ﬁre’’
radiation is more effective. In this regard, beta-emitting
radionuclides, which kill cells preferentially by ‘‘cross-ﬁre’’
[15], have been successfully used for therapy of leukemia, a
single-cell disease [49], and in preclinical RIT of systemic
fungal infections [16,39,50]. (3) In contrast to immunotoxins,
the radioisotope linked to the antibody is unlikely to elicit
signiﬁcant immune responses that would limit subsequent
use. (4) RIT is potentially less toxic than immunotoxins,
because the chemistry of linking different radioisotopes
including
188Re and
213Bi to the antibodies has been well
developed, and the exceptional stability of radiolabeled mAbs
in vitro and in vivo has been conﬁrmed [15,42,51]. (5) The
availability of many isotopes differing in half-life and
radiation type [15] offers great versatility for designing RIT.
Nevertheless, combination therapy consisting of RIT and
immunotoxins may provide greater advantages than either
modality alone.
We have recently shown that RIT of infection works
through the combination of cell-killing mechanisms such as
‘‘direct hit’’ and ‘‘cross-ﬁre,’’ promotion of apoptotic death of
targeted cells, generation of reactive oxygen species and
modulation of the inﬂammatory response [50]. All of these
mechanisms require certain levels of radioactivity to manifest
themselves. It is likely that in our study the threshold dose at
which those mechanisms become effective in killing HIV-
infected cells is in the range 40–80 (1.48–2.96 MBq) lCi.
There are numerous published data on the existence of
threshold RIT doses below which no therapeutic effects on
tumors in animals are observed and above which the effects
quickly reach maximum [42, 52]. However, determination of
Table 1. Biodistribution of
188Re-246-D mAb in thy/liv-SCID-hu Mice Uninfected and Infected with HIV Examined 18 h after
Intraperitoneal Injection
Organ Uptake in HIV-Infected Mice, % ID/g
a Uptake in Noninfected Mice, % ID/g
a
Blood 10.7 (0.5) 6.7 (0.4)
Implant 2.45 (0.08) 1.85 (0.08)
Kidneys 10.9 (0.5) 9.3 (0.1)
Liver 3.1 (0.4) 1.8 (0.4)
Spleen 3.3 (1.0) 1.6 (0.5)
Each value is the mean for three mice per group.
aStandard deviation of the mean is given in parentheses
doi:10.1371/journal.pmed.0030427.t001
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importance as in the clinic this therapy is administered as
maximum tolerated dose (MTD) to maximize the therapeutic
effect. These results establish that RIT can effectively target
and kill HIV-1-infected hPBMCs in vivo.
Based on the data accumulated in clinical RIT of cancer,
the primary toxic effect of RIT applied to infections is likely
to be bone marrow suppression. Important determinants of
the extent and duration of myelosuppression include bone
marrow reserve (based on prior cytotoxic therapy and extent
of disease involvement), total infection burden, and spleen
size [53,54]. Nevertheless, RIT of non-Hodgkin lymphoma is
effective in patients who have received several unsuccessful
courses of chemotherapy and consequently have depleted
bone marrow reserves and weakened immunity—not unlike
some patients with advanced HIV-1 infection. The applica-
tion of RIT to infectious diseases will require optimization of
the dose to ascertain and minimize toxic effects.
In addition, when using a radioactive therapy in patients
there is always a concern of long-term effects such as the
possible subsequent development of neoplasms arising from
radiation-induced mutations. However, this risk should be
extremely low after short-term exposure and would likely be
outweighed by the beneﬁts of treating or preventing HIV
infections [55]. It is also extremely unlikely that particulate
radiation utilized in RIT will cause mutation of the HIV virus,
the genomic information of which is carried by two positive
RNA strands and not by DNA, and ionizing radiation is a
weak mutagen compared to chemical mutagens [56]. Fur-
thermore, HIV replication already has an inherently high rate
of viral mutation.
Acutely exposed individuals lack HIV-speciﬁc antibodies
that could reduce the effectiveness of RIT by competitively
binding to gp41, so RIT could be used for treatment initiated
after HIV exposure. However, the effectiveness of treatment
in patients with established HIV infection may be reduced by
competition between the radionuclide-linked antibody and
the patient’s own antiviral antibodies directed to the same
antigen on HIV-1-infected cells. If this competition occurs, it
could be circumvented by increasing the RIT antibody dosage
or by coupling the radionuclides to very high afﬁnity
antibodies likely to bind more effectively to the gp41 than
self-antibodies. The latter approach would be enhanced by
using cocktails of mAbs against noncompeting epitopes and,
following the well-known radiation oncology approach of
dose fractionation, each antibody in the antibody cocktail
would carry a partial dose (one-half or one-third, depending
on the composition of the cocktail). Our group is currently
investigating the role of competition between radiolabeled
mAb 246-D and cold polyclonal human anti-gp41 antibody
binding to HIV-1 gp41 and killing HIV-1-infected cells.
If advanced to clinical use, RIT might be most effective
when used in combination with HAART [57], which blocks
virus replication in newly infected cells. The major ther-
apeutic use of RIT will likely be as an adjunct with HAART to
prevent HIV infection when administered to individuals
within the ﬁrst days of exposure to HIV. Even if infection is
not prevented in some cases, initial treatment of patients
soon after infection may reduce the initial number of HIV-1-
infected cells and thereby reduce viral set point. RIT also may
be a useful adjunct for protocols designed to ‘‘ﬂush out’’
quiescent, latently infected lymphocytes by the administra-
Figure 5. RIT Using Anti-gp41 mAb
188Re-246-D Reduces HIV Infection in the Human Thymic Implants of thy/liv-SCID-hu Mice
One week after thy/liv-SCID-hu mice were infected with HIV-1, they were treated by intraimplant injection of two doses of either
188Re-246-D (n¼4) or
188Re-1418 control mAb (n ¼ 4) given on two consecutive days (p ¼ 0.11).
(A) The number of HIV-infected thymocytes was determined 3 d later. The bars show mean number (error bars show standard error of the mean) of HIV-
infected thymocytes/10
6 thymocytes in the human thymic implants of thy/liv-SCID-hu mice treated with
188Re-246-D or
188Re-1418 control mAb.
(B) Comparison of the number of HIV-infected thymocytes in the human thymic implants in each of the four treated thy/liv-SCID-hu mice before
treatment was initiated and after treatment with
188Re-246-D.
doi:10.1371/journal.pmed.0030427.g005
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replication [58]. Moreover, since viral resistance is often a
result of mutations introduced during replication, a therapy
that reduces the number of HIV-producing cells may reduce
the emergence of drug-resistant strains. To avoid selection of
cells harboring antibody-resistant viruses, a cocktail of mAbs
to various epitopes on the HIV envelope may be desirable.
We envision that the availability of RIT could provide a novel
treatment option that may hasten the day when curative
regimens are available for the eradication of HIV-1 infection.
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Editors’ Summary
Background. In a person infected with HIV, the symptoms of AIDS can
be delayed or controlled with drug combinations such as highly active
antiretroviral therapy (HAART). However, at the moment there is no cure
for HIV infection or AIDS; HAART has to be taken for life and has
unpleasant side effects, and the HIV virus can become resistant to some
of the drugs. Even in people for whom HAART is successfully controlling
disease, HIV remains at very low levels in white blood cells, and is
capable of infecting more cells if treatment is stopped for some reason
or becomes ineffective because the virus has developed resistance. One
possible approach that could potentially eradicate HIV in an infected
person is to inject antibodies, targeted against elements of the HIV
particle, joined to a radioactive ‘‘tag.’’ The idea is that the antibodies
would bind to HIV particles at the surface of infected white blood cells,
and the radioactivity would then kill the infected cell. This strategy, called
‘‘radioimmunotherapy,’’ has been successfully used to develop treat-
ments for certain cancers.
Why Was This Study Done? The researchers wanted to find out
whether radioimmunotherapy had any potential for treating HIV
infection. As the first step, they needed to find out whether radioactive
antibodies targeted against HIV proteins could kill HIV infected cells in
animals, and also whether the animals suffered any serious side effects as
a result. This is an early step in developing new treatments that would
need to show promising results before the approach would be tried in
humans.
What Did the Researchers Do and Find? The researchers first did some
experiments on HIV-infected white blood cells in vitro (i.e., test tube
experiments), and second in vivo on HIV-infected PBMCs in the spleens
of mice. They found that in vitro, HIV-infected white blood cells were
successfully killed by radioactive antibodies that had been developed
against specific proteins in the HIV particle that are routinely displayed at
the surface of infected cells. Two different types of antibody, and two
different types of radioactive tag, were tried. Both antibodies were very
effective in targeting HIV infected cells, but one type of radioactive tag
(bismuth 213) was better than the other (rhenium 188). Then, SCID mice
were infected intrasplenically with HIV-infected PBMCs and treated with
the radioactively tagged antibodies (these particular mice had a deficient
immune system, which means that they tolerate transplanted HIV-
infected human PBMCs that serve as in vivo targets for the radioactive
antibodies. The number of HIV-infected human PBMCs was reduced in
the treated mice compared with control animals, which were treated
with antibodies not joined to a radioactive tag. The greater the antibody
dose, the greater the proportion of HIV-infected human PBMC that were
killed. Finally, the researchers also looked at whether the antibody
treatment damaged platelets in the infected mice, and they saw a drop
in platelet numbers only for the mice receiving the highest dose of
antibodies.
What Do These Findings Mean? These results provide preliminary
support for the idea that radioimmunotherapy might be an approach for
treatment of HIV. They argue that additional experiments in animals are
warranted. If those continue to be promising, it will be critical to find out
whether the radioactively labeled antibodies are safe in humans, and
whether they are effective. The researchers who did this study feel that
the strategy, if eventually shown to be safe and effective, would likely be
of most value in preventing HIV infection very shortly after someone is
exposed to the virus or treating HIV-infected patients not responsive to
anti-retroviral therapy.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030427.
  The Medline Plus (provided by the US National Library of Medicine)
encyclopedia has an entry on HIV/AIDS
  The AIDSMap provides patient information on HIV/AIDS treatment and
care
  The US Centers for Disease Control and Prevention has resources on
HIV/AIDS treatment, including current treatment guidelines
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